Impact of Sample Preparation Methods on LC-MS/MS Analysis of Molecular Targeted Drugs

Yusuke Tanaka, Takuya Araki, Hideaki Yashima, Koujirou Yamamoto

Abstract

The therapeutic efficacy of molecular targeted drugs (MTD)s and the risk of certain adverse drug effects are closely related to their blood concentrations, highlighting the importance of optimizing dosage based on therapeutic drug monitoring. In this study, we compared four pretreatment methods for the analysis of 15 MTDs by LC-MS/MS: protein precipitation (PPT), solid-phase extraction (SPE) using a reversed-phase (RP) column, SPE using a mixed-mode cation-exchange RP column, and supported liquid extraction (SLE), and evaluated their effects on recovery rates and matrix effects. While PPT showed high recovery rates (>80%) for 8 out of 15 compounds, certain highly polar MTDs exhibited significant peak intensity decreases with repeated analyses, indicating potential issues with ion suppression due to impurities. SPE using a reversed-phase column (HLB) resulted in low recovery rates for 12 out of 15 compounds. In contrast, SPE using an MCX column yielded high recovery rates (>80%) for 14 out of 15 compounds but exhibited substantial matrix effects for 9 out of 15 compounds (matrix factors >2). Addressing these matrix effects required sample dilution, and achieving higher sensitivity would necessitate extensive method adjustments tailored to each compound. SLE demonstrated the most favorable results, with the largest number of compounds showing acceptable recovery rates and minimal matrix effects. In conclusion, these findings, based on standard protocols from product manuals, suggest that while method optimization could improve performance for specific compounds, SLE appears to be the most suitable first-choice pretreatment method for the LC-MS/MS analysis of MTDs due to its balance of recovery and matrix effect control.

Full Text:

PDF

References

Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol 2021;77:441–64.

He S, Bian J, Shao Q, Zhang Y, Hao X, Luo X, et al. Therapeutic drug monitoring and individualized medicine of dasatinib: Focus on clinical pharmacokinetics and pharmacodynamics. Front Pharmacol 2021;12:797881.

Henriksen JN, Andersen CU, Fristrup N. Therapeutic drug monitoring for tyrosine kinase inhibitors in metastatic renal cell carcinoma. Clin Genitourin Cancer 2024;22:102064.

Maeda A, Irie K, Hashimoto N, Fukushima S, Ando H, Okada A, et al. Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report. Invest New Drugs 2021;39:272–7.

Brown K, Comisar C, Witjes H, Maringwa J, de Greef R, Vishwanathan K, et al. Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer. Br J Clin Pharmacol 2017;83:1216–26.

Tuzimski T, Petruczynik A. Review of chromatographic methods coupled with modern detection techniques applied in the therapeutic drugs monitoring (TDM). Molecules 2020;25:4026.

Ishikawa Y, Araki T, Sato TM, Yashima H, Nagano D, Yamamoto K. Development of a quantitative method for sunitinib N-oxide. Indones J Pharm 2021;3:61–70.

Birch M, Morgan PE, Handley S, Ho A, Ireland R, Flanagan RJ. Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib: Therapeutic drug monitoring of dasatinib and imatinib. Biomed Chromatogr 2013;27:335–42.

Takenaka M, Takahashi Y, Yashima H, Araki T, Yamamoto K. The Impact of Sunitinib N-oxide as a Photodegradation Product of Sunitinib. Indones J Pharm 2019;1:19–25.

Sekizaki N, Yashima H, Araki T, Yamamoto K. Simple and Rapid Method for Determination of Abemaciclib in Human Serum using Supported Liquid Extraction Pretreatment and LC-MS/MS Analysis. Indones J Pharm 2020;2:97–103.

Turković L, Mutavdžić Pavlović D, Mlinarić Z, Skenderović A, Silovski T, Sertić M. Optimisation of Solid-Phas LC-MS/MS Analysis of Six Breast Cancer Drugs in Patient Plasma Samples. Pharmaceuticals 2023;16. https://doi.org/10.3390/ph1610144 5.

Sumimoto T, Nakahara R, Suzuki Y, Tanaka R, Yoshida N, Ogata M, et al. Development of a sensitive and high-throughput assay for simultaneous quantification of 5 tyrosine kinase inhibitors and 2 active metabolites in human plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry. Ther Drug Monit 2022;44:419–29.

e Extraction and

DOI: https://doi.org/10.24198/idjp.v7i1.60748

Refbacks

  • There are currently no refbacks.